{"id":"viread","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Depression","drugRate":"","severity":"common","organSystem":""},{"effect":"Asthenia","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Insomnia","drugRate":"","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Pyrexia","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Acute nephropathy","Aggressive behavior","Breastfeeding (mother)","Chronic hepatitis C","Congenital long QT syndrome","Depressive disorder","Disease of liver","Fanconi syndrome","Hepatic failure","Hypercholesterolemia","Hypertriglyceridemia","Hypophosphatemia","Kidney disease","Lactic acidosis","Liver function tests abnormal","Mania","Obesity","Osteomalacia","Osteopenia","Paranoid disorder","Pathological fracture","Pregnancy, function","Prolonged QT interval","Seizure disorder","Severe depression","Steatosis of liver","Suicidal thoughts","Torsades de pointes"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Bone Mineral Density decrease at lumbar spine","drugRate":"28%","severity":"serious"},{"effect":"Fasting cholesterol elevation","drugRate":"19%","severity":"serious"},{"effect":"Fasting triglyceride elevation","drugRate":"1%","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL1486","moleculeType":"Small molecule","molecularWeight":"635.52"},"aliases":["tenofovir disoproxil fumarate","Tenofovir disoproxil fumarate 300mg"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Viread","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:49:07.539859+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:49:13.747305+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Viread","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:49:14.464001+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Human immunodeficiency virus type 1 reverse transcriptase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:49:15.038711+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1486/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:49:14.939048+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"1fdae465-2c01-4030-a73c-fd2f13368453","title":"VIREAD ACCESS (TENOFOVIR DISOPROXIL FUMARATE) TABLET, COATED [GILEAD SCIENCES, INC.]"},"ecosystem":[],"mechanism":{"target":"Gag-Pol polyprotein, Reverse transcriptase/RNaseH"},"_scrapedAt":"2026-03-28T00:15:14.239Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:49:16.883850+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Chronic type B viral hepatitis","diseaseId":"chronic-type-b-viral-hepatitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Human immunodeficiency virus infection","diseaseId":"human-immunodeficiency-virus-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07498153","phase":"NA","title":"Spotting Syphilis: A Dual Point-of-Care Syphilis Screening Initiative in a Low-Resource Healthcare Setting","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2025-09-30","conditions":"Syphilis, HIV Infections","enrollment":149},{"nctId":"NCT07266831","phase":"PHASE2, PHASE3","title":"A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-18","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":570},{"nctId":"NCT04223791","phase":"PHASE3","title":"Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":643},{"nctId":"NCT05652478","phase":"PHASE2","title":"Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Healthy Volunteer, Weight Gain, Metabolic Effects","enrollment":120},{"nctId":"NCT07497594","phase":"NA","title":"ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention","status":"RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2026-02-03","conditions":"Contact With or Exposure to Human Immunodeficiency Virus","enrollment":1500},{"nctId":"NCT02881320","phase":"PHASE2, PHASE3","title":"Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2016-09-21","conditions":"HIV-1 Infection","enrollment":177},{"nctId":"NCT07071623","phase":"PHASE3","title":"A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-10","conditions":"Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis","enrollment":4580},{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT07044297","phase":"PHASE3","title":"A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-31","conditions":"Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis","enrollment":4390},{"nctId":"NCT05373758","phase":"NA","title":"A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-02-07","conditions":"HIV Infections, AIDS, Virologic Failure","enrollment":648},{"nctId":"NCT02720094","phase":"PHASE2, PHASE3","title":"Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12-19","conditions":"HIV Infections","enrollment":4570},{"nctId":"NCT07476339","phase":"PHASE4","title":"REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE: A Multi-Center, Single-Arm, Open-Label, Phase 4 Study Assessing the Safety and Efficacy of B/F/TAF in HIV-Positive Adults Returning to Care After Experiencing a Treatment Interruption of ≥12 Weeks","status":"NOT_YET_RECRUITING","sponsor":"CAN Community Health","startDate":"2026-03-23","conditions":"HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV","enrollment":200},{"nctId":"NCT07473778","phase":"","title":"Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention","status":"NOT_YET_RECRUITING","sponsor":"Gilead Sciences","startDate":"2026-03","conditions":"HIV Infections","enrollment":3000},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT07125235","phase":"NA","title":"Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clinical Trial","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-02-09","conditions":"Behavioral Intervention, Viral Suppression of HIV Infection, ART Adherence","enrollment":270},{"nctId":"NCT06511063","phase":"PHASE2","title":"Antiviral Clinical Trial for Long Covid-19","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2024-10-01","conditions":"Long Covid","enrollment":90},{"nctId":"NCT07202546","phase":"PHASE2","title":"A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2026-02-11","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT07462611","phase":"NA","title":"HIV Pre-Exposure Prophylaxis (PrEP) Linkage With Immediate Medications in the Emergency Department Study","status":"NOT_YET_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-03-30","conditions":"HIV Pre-exposure Prophylaxis, PrEP","enrollment":250},{"nctId":"NCT07055451","phase":"PHASE1","title":"Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-08-12","conditions":"HIV-1-infection","enrollment":16},{"nctId":"NCT07459426","phase":"","title":"Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)","status":"NOT_YET_RECRUITING","sponsor":"Yaşar Bayındır, MD","startDate":"2026-03-15","conditions":"Hepatitis B, Chronic","enrollment":700},{"nctId":"NCT07001319","phase":"PHASE1","title":"Study of GS-3242 in Participants With HIV-1; Substudy-05","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-05-29","conditions":"HIV-1-infection","enrollment":30},{"nctId":"NCT05993767","phase":"PHASE2","title":"UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2024-12-11","conditions":"HIV Infection","enrollment":53},{"nctId":"NCT04979728","phase":"","title":"HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-05-27","conditions":"HIV Treatment, HIV Prevention","enrollment":150},{"nctId":"NCT02932150","phase":"PHASE2","title":"Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2016-11","conditions":"Chronic Hepatitis B","enrollment":150},{"nctId":"NCT06101342","phase":"PHASE2","title":"Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-12-13","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":181},{"nctId":"NCT04375800","phase":"PHASE2","title":"Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-03","conditions":"Human Immunodeficiency Virus (HIV) Infection","enrollment":84},{"nctId":"NCT04496882","phase":"PHASE4","title":"Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-09-09","conditions":"Chronic Hepatitis b, Hepatitis B Reactivation","enrollment":260},{"nctId":"NCT05630638","phase":"PHASE4","title":"Doravirine Dose Optimisation in Pregnancy","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2023-10-10","conditions":"HIV","enrollment":76},{"nctId":"NCT05705427","phase":"PHASE4","title":"The COMBAT HBV Feasibility Trial","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-08-17","conditions":"Hepatitis B, Vertical Transmission of Infectious Disease","enrollment":317},{"nctId":"NCT04341779","phase":"NA","title":"Simplifying Treatment and Monitoring for HIV (STREAM HIV)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-02-04","conditions":"HIV/AIDS, HIV-1-infection","enrollment":539},{"nctId":"NCT05353283","phase":"NA","title":"PrEP Point-of-Care Brief-Intervention for Adherence Among Young Men Who Have Sex With Men","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2023-09-01","conditions":"Risk Reduction","enrollment":63},{"nctId":"NCT02020083","phase":"","title":"Placental Transfer of Tenofovir","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-02","conditions":"Pregnant Women","enrollment":369},{"nctId":"NCT07349758","phase":"PHASE1","title":"Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-01-06","conditions":"Healthy Volunteer, HIV Prevention","enrollment":24},{"nctId":"NCT04898699","phase":"EARLY_PHASE1","title":"IPrEP Men's Study: Expanding the Reach of Prevention for Men in Kisumu, Kenya","status":"COMPLETED","sponsor":"Columbia University","startDate":"2021-11-24","conditions":"HIV","enrollment":120},{"nctId":"NCT06104306","phase":"PHASE4","title":"Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2023-12-13","conditions":"HIV-1-infection","enrollment":33},{"nctId":"NCT04431245","phase":"","title":"Stopping Antiviral Treatment in Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2021-06-01","conditions":"Chronic Hepatitis b","enrollment":54},{"nctId":"NCT06963710","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)","status":"RECRUITING","sponsor":"Aligos Therapeutics","startDate":"2025-07-15","conditions":"Chronic Hepatitis B Infection","enrollment":200},{"nctId":"NCT05052996","phase":"PHASE2","title":"Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-10-05","conditions":"HIV-1 Infection","enrollment":142},{"nctId":"NCT04644029","phase":"PHASE3","title":"Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-24","conditions":"HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis","enrollment":730},{"nctId":"NCT04820933","phase":"EARLY_PHASE1","title":"Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-03-01","conditions":"HIV I Infection, Cardiovascular Risk Factor, Lipid Metabolism Disorders","enrollment":26},{"nctId":"NCT01651403","phase":"PHASE3","title":"Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2012-12-06","conditions":"Chronic Hepatitis B","enrollment":90},{"nctId":"NCT04233879","phase":"PHASE3","title":"Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-28","conditions":"HIV-1 Infection","enrollment":599},{"nctId":"NCT04564547","phase":"PHASE2","title":"Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-03-09","conditions":"HIV-1 Infection","enrollment":161},{"nctId":"NCT07357584","phase":"PHASE4","title":"Efficacy and Safety of Doravirine in the Rapid Initiation","status":"NOT_YET_RECRUITING","sponsor":"Fundación Huésped","startDate":"2026-07-13","conditions":"HIV-1-infection","enrollment":100},{"nctId":"NCT05763576","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2023-04-28","conditions":"Chronic Hepatitis B","enrollment":60},{"nctId":"NCT06560684","phase":"PHASE2","title":"CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-10-29","conditions":"Tenofovir","enrollment":150},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Hepatitis B","enrollment":58},{"nctId":"NCT02738008","phase":"PHASE2","title":"Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-03","conditions":"Hepatitis B","enrollment":12},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT02604212","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-11","conditions":"Hepatitis B","enrollment":32},{"nctId":"NCT02797522","phase":"PHASE1","title":"A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-06","conditions":"Hepatitis B","enrollment":47},{"nctId":"NCT01854775","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-05-06","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":129},{"nctId":"NCT06203132","phase":"PHASE3","title":"DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-01-27","conditions":"HIV-1-infection","enrollment":610},{"nctId":"NCT06544733","phase":"PHASE2, PHASE3","title":"Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-20","conditions":"HIV-1-Infection","enrollment":675},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT06132386","phase":"","title":"Analysis of Cellular Kinases and Aging in PBMCs and Colorectal Tissue","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2023-08-07","conditions":"HIV Infections, Aging","enrollment":21},{"nctId":"NCT04925752","phase":"PHASE3","title":"Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-06-28","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":3292},{"nctId":"NCT07295873","phase":"PHASE1","title":"Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2025-12-30","conditions":"Chronic Hepatitis B Liver Fibrosis, DDI (Drug-Drug Interaction)","enrollment":64},{"nctId":"NCT04782180","phase":"PHASE4","title":"PrEP at a Syringe Services Program","status":"COMPLETED","sponsor":"University of Miami","startDate":"2022-02-01","conditions":"Hiv, Substance Use Disorders","enrollment":90},{"nctId":"NCT03696160","phase":"PHASE3","title":"The Late Presenter Treatment Optimisation Study","status":"COMPLETED","sponsor":"NEAT ID Foundation","startDate":"2019-03-05","conditions":"HIV/AIDS","enrollment":447},{"nctId":"NCT04222504","phase":"NA","title":"Community-based Venues for Delivery of Healthcare Services: Proof of Concept Pilot","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-02-08","conditions":"Pre-Exposure Prophylaxis, STI, Contraceptive Usage","enrollment":500},{"nctId":"NCT04742491","phase":"PHASE2, PHASE3","title":"Pre-Exposure Prophylaxis for Transgender Women in the US and South America","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2021-03-26","conditions":"HIV Prevention","enrollment":304},{"nctId":"NCT02591420","phase":"PHASE1","title":"Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT01198860","phase":"","title":"Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B","status":"APPROVED_FOR_MARKETING","sponsor":"Nguyen Thi Trieu, MD","startDate":"","conditions":"CHRONIC HEPATITIS B","enrollment":""},{"nctId":"NCT06766331","phase":"NA","title":"Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2028-04-03","conditions":"Opioid Use Disorder, HIV, Hepatitis C Virus","enrollment":60},{"nctId":"NCT04274595","phase":"NA","title":"Role of Reverse Transcriptase Inhibitors in the Treatment of Psoriasis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2020-02-13","conditions":"Psoriasis","enrollment":8},{"nctId":"NCT04429971","phase":"NA","title":"Pre-Exposure Prophylaxis in the Emergency Department","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2020-03-18","conditions":"HIV/AIDS, PrEP","enrollment":26},{"nctId":"NCT05979311","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-02-09","conditions":"HIV, HIV Infections","enrollment":473},{"nctId":"NCT07258251","phase":"PHASE4","title":"Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach","status":"NOT_YET_RECRUITING","sponsor":"The Task Force for Global Health","startDate":"2026-01-01","conditions":"Chronic Hepatitis B, Hepatitis B Virus Infection","enrollment":6000},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT05911360","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-01-31","conditions":"HIV, HIV Infections","enrollment":205},{"nctId":"NCT06613685","phase":"PHASE2, PHASE3","title":"Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-21","conditions":"HIV-1-infection","enrollment":675},{"nctId":"NCT05719441","phase":"PHASE2","title":"A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-08-19","conditions":"Acute HIV Infection","enrollment":48},{"nctId":"NCT05630755","phase":"PHASE3","title":"A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-17","conditions":"HIV-1 Infection","enrollment":514},{"nctId":"NCT05797714","phase":"NA","title":"The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2022-06-08","conditions":"HBV Infection, Chronic Hepatitis b","enrollment":200},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT02842086","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2016-09-02","conditions":"Pre-Exposure Prophylaxis of HIV-1 Infection","enrollment":5399},{"nctId":"NCT03670355","phase":"PHASE1","title":"Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-01-02","conditions":"HIV Infections","enrollment":49},{"nctId":"NCT06630286","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-09","conditions":"HIV-1-infection","enrollment":609},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT06333808","phase":"PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-03-25","conditions":"HIV-1-infection","enrollment":577},{"nctId":"NCT02452528","phase":"PHASE2","title":"Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-08","conditions":"Chronic Hepatitis B","enrollment":4},{"nctId":"NCT05322629","phase":"NA","title":"Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2022-09-07","conditions":"Hiv","enrollment":650},{"nctId":"NCT06962592","phase":"NA","title":"Mentor Moms+ Study","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2025-09-15","conditions":"HIV, Alcohol Consumption","enrollment":100},{"nctId":"NCT05333679","phase":"NA","title":"Urine Tenofovir Point-of-care Test to Identify Patients in Need of ART Adherence Support (UTRA Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-03-02","conditions":"Risk Reduction","enrollment":200},{"nctId":"NCT05140954","phase":"PHASE2, PHASE3","title":"The Women TAF-FTC Benchmark Study","status":"COMPLETED","sponsor":"University of Washington","startDate":"2023-03-28","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT03935464","phase":"NA","title":"Point-of-care Urine Monitoring of Adherence: Testing a Real-Time Urine Assay of Tenofovir in PrEP","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-03-01","conditions":"Risk Reduction","enrollment":100},{"nctId":"NCT05957913","phase":"PHASE2","title":"Effects of Antiviral Therapies on Epstein-Barr Virus Replication","status":"ENROLLING_BY_INVITATION","sponsor":"Massachusetts General Hospital","startDate":"2023-06-05","conditions":"Multiple Sclerosis","enrollment":50},{"nctId":"NCT07115368","phase":"PHASE1","title":"Study of GS-1219 in Participants With HIV-1","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2025-08-11","conditions":"HIV-1-infection","enrollment":4},{"nctId":"NCT06891066","phase":"PHASE2","title":"A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-14","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":150},{"nctId":"NCT06564792","phase":"NA","title":"Contingency Management in HIV Care for Both Stimulant Use & ART Adherence","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2023-09-15","conditions":"Stimulant Use (Diagnosis), Hiv","enrollment":37},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT03164564","phase":"PHASE3","title":"Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-11-07","conditions":"HIV Infections","enrollment":3224},{"nctId":"NCT04704024","phase":"PHASE3","title":"Reducing Vertical Transmission of Hepatitis B in Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-09-03","conditions":"Hepatitis B Infection","enrollment":450},{"nctId":"NCT07210528","phase":"PHASE1","title":"Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore Study","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-06-30","conditions":"Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD)","enrollment":48},{"nctId":"NCT04734652","phase":"PHASE2","title":"INSTI's For The Management of HIV-associated TB","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2022-02-18","conditions":"HIV/AIDS, Tuberculosis, Pulmonary","enrollment":122},{"nctId":"NCT03360682","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2018-04-13","conditions":"HIV-1-infection, Solid Organ Transplant","enrollment":19},{"nctId":"NCT06497465","phase":"PHASE3","title":"Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-09-18","conditions":"Tuberculosis, HIV","enrollment":150},{"nctId":"NCT05528653","phase":"PHASE4","title":"Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: \"e-PrEP\"","status":"COMPLETED","sponsor":"Vivent Health","startDate":"2022-07-19","conditions":"HIV Prevention","enrollment":75},{"nctId":"NCT06101329","phase":"PHASE2","title":"Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-11-17","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":253}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1486"},"formularyStatus":[],"_approvalHistory":[{"date":"20190424","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20050512","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20180730","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20131023","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20130724","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20120118","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20160216","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20091110","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20120816","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20101001","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20081104","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20120807","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20100115","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20080516","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20060308","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20031014","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20030815","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20181211","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20021202","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20040701","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20150529","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20170407","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20130402","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20160310","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20130312","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20110919","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20151118","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20101014","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20091007","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20111118","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20100324","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20080811","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20051130","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20011026","type":"ORIG","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20031031","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20070521","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA021356"},{"date":"20151202","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA022577"},{"date":"20131023","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA022577"},{"date":"20130402","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA022577"},{"date":"20120816","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA022577"},{"date":"20190424","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA022577"},{"date":"20180730","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA022577"},{"date":"20120118","type":"ORIG","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA022577"},{"date":"20160216","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA022577"},{"date":"20150529","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA022577"},{"date":"20130724","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA022577"},{"date":"20120807","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA022577"},{"date":"20181211","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA022577"},{"date":"20170407","type":"SUPPL","sponsor":"GILEAD SCIENCES INC","applicationNumber":"NDA022577"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":72,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Viread","genericName":"Viread","companyName":"Replicor Inc.","companyId":"replicor-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:49:16.883850+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}